iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech
innovator and biologics contract manufacturing organization, today
announced the appointment of Martin B. Brenner, DVM, Ph.D., as its
Chief Scientific Officer (“CSO”), effective January 18, 2020.
“We are thrilled to have Dr. Brenner join our
team,” said Tom Isett, Chairman & CEO of iBio. “Given his prior
experience leading organizations with novel protein expression
platforms to build proprietary product pipelines, Dr. Brenner
should be uniquely suited to assist iBio with a similar
transformation. Notably, he also brings a track-record of effective
new target search and evaluation, as well as establishing
productive collaborations.”
Dr. Brenner has a strong history of success
heading drug discovery and development teams at several of the
world’s leading pharmaceutical companies, including AstraZeneca,
Eli Lilly and Company (“Lilly”), Pfizer Inc. (“Pfizer”), and Merck
Research Laboratories (“Merk”). Most recently, Dr. Brenner served
as the CSO at Pfenex Inc. (“Pfenex”), a NYSEA-listed company which,
using its patented Pfēnex Expression Technology® platform, created
an advanced pipeline of therapeutic equivalents, vaccines,
biologics and biosimilars. Pfenex was acquired by Ligand
Pharmaceuticals Incorporated for approximately $516 million in
October 2020.
Previously, Dr. Brenner served as the CSO at
Recursion Pharmaceuticals, Inc. (“Recursion”), a company focused on
accelerating drug discovery for rare diseases and diseases with
high unmet medical need. Prior to his time at Recursion, he was
Vice President and Head of Research & Early Development at
Stoke Therapeutics, Inc. (“Stoke”), a biotechnology company using
antisense oligonucleotides to increase gene expression for the
treatment of rare diseases. Prior to Stoke, he was Executive
Director at Merck, where he built a biotech unit from scratch,
focusing his team’s research on diabetes and nonalcoholic
steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the
Senior Director and Head of cardiovascular, renal, and metabolism
(CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an
Associate Research Fellow at Pfizer where he led the islet biology
and in vivo pharmacology in the CVMED Target Exploration Unit
before assuming the role of Head of the Insulin Resistance
Group.
“It has been captivating to watch the scale,
scope and speed with which iBio has successfully transformed itself
into a dynamic and diversified biotechnology company,” said Dr.
Brenner. “That was made possible by iBio combining its proprietary
FastPharming® and Glycaneering™
technologies to better control the way in which its plant-based
expression system glycosylates proteins, thereby possibly improving
the quality and, potentially in some cases, the efficacy of the
biologics it produces. I am looking forward to being part of the
iBio team as the Company executes the next stage of its growth
strategy and seeks to expand its pipeline of innovative product
candidates focused on pulmonology, oncology and fibrotic
diseases.”
Dr. Brenner earned his DVM at the Ludwig
Maximilian University of Munich and his Ph.D. in Pharmacology at
the Veterinary School of Hannover in Hannover, Germany. He received
the Lilly Endocrine Research Award of Merit for Science, as well as
the Lilly Pinnacle Award for Quality for Good Research
Practice.
About iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming® System
combines vertical farming, automated hydroponics, and glycan
engineering technologies to rapidly deliver high-quality monoclonal
antibodies, vaccines, bioinks and other proteins. iBio is
developing proprietary products on the
FastPharming Platform, which include
biopharmaceuticals for the treatment of fibrotic and infectious
diseases, amongst others. The Company’s subsidiary, iBio CDMO LLC,
provides FastPharming Contract
Development and Manufacturing Services along with the
Glycaneering Development Service™ for
engineering high-performance recombinant glycoproteins. For more
information, visit www.ibioinc.com.
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the
federal securities laws. Words such as “may,” “might,” “will,”
“should,” “believe,” “expect,” “anticipate,” “estimate,”
“continue,” “predict,” “forecast,” “project,” “plan,” “intend” or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding the expected
contribution of Dr. Brenner and the Company expanding its pipeline
of innovative product candidates focused on pulmonology, oncology
and fibrotic diseases. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward-looking statements are subject to various risks and
uncertainties, many of which are difficult to predict that could
cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the contribution of Dr. Brenner, the
Company’s ability to obtain regulatory approvals for
commercialization of its product candidates, including its
infectious disease vaccines, or to comply with ongoing regulatory
requirements, regulatory limitations relating to its ability to
promote or commercialize its product candidates for specific
indications, acceptance of its product candidates in the
marketplace and the successful development, marketing or sale of
products, its ability to maintain its license agreements, the
continued maintenance and growth of its patent estate, its ability
to establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities, competition, its ability to retain its key
employees or maintain its NYSE American listing, and the other
factors discussed in the Company’s Annual Report on Form 10-K for
the year ended June 30, 2020 and the Company’s subsequent filings
with the SEC, including subsequent periodic reports on Form 10-Q
and Form 8-K. The information in this release is provided only as
of the date of this release, and we undertake no obligation to
update any forward-looking statements contained in this release on
account of new information, future events, or otherwise, except as
required by law.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024